

# INPLASY

## Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease: A Systematic Review

INPLASY2024120012  
doi: 10.37766/inplasy2024.12.0012  
Received: 3 December 2024  
Published: 3 December 2024

Ni, XF; Zhang, LL.

**Corresponding author:**  
Xiaofeng Ni

nixiaofenger@163.com

**Author Affiliation:**  
West China Second University  
Hospital, Sichuan University.

### ADMINISTRATIVE INFORMATION

**Support** - No Funding source/sponsor.

**Review Stage at time of this submission** - The review has not yet started.

**Conflicts of interest** - None declared.

**INPLASY registration number:** INPLASY2024120012

**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 3 December 2024 and was last updated on 3 December 2024.

### INTRODUCTION

**Review question / Objective** Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease.

**Condition being studied** Very Early Onset Inflammatory Bowel Disease.

### METHODS

**Participant or population** Very Early Onset Inflammatory Bowel Disease.

**Intervention** Anti-Tumor Necrosis Factor Alpha.

**Comparator** Other agents.

**Study designs to be included** Randomised controlled trials, non-randomised controlled trials, cohort studies, case-control studies, case series studies.

**Eligibility criteria** (a) study type: randomized controlled trials (RCTs), cohort studies, case-control studies, and case series studies; (b) studies carried out in children with very early onset inflammatory bowel disease; (c) therapy with anti-tumor necrosis factor alpha alone or in combination with other agents.

**Information sources** PubMed, EMBASE and Cochrane Library databases.

**Main outcome(s)** (a) clinical remission; (b) clinical response; (c) corticosteroid-free clinical remission; (d) endoscopic remission; (e) endoscopic improvement; (f) safety.

**Quality assessment / Risk of bias analysis** The Cochrane Risk of Bias tool will be used for RCTs and the Newcastle–Ottawa Scale (NOS) will be used for cohort studies. A validated quality assessment tool developed by the Canadian Institute of Health Economics (IHE) will be used for case series.

---

**Strategy of data synthesis** Perform meta-analysis or descriptive analysis according to the data. Continuous parametric data are expressed as mean and standard deviation (SD), while non-parametric data are expressed as median followed by range or interquartile range (IQR).

**Subgroup analysis** Different dose.

**Sensitivity analysis** NA.

**Country(ies) involved** China.

**Keywords** Anti-Tumor Necrosis Factor Alpha, Very Early Onset Inflammatory Bowel Disease, Systematic Review.

**Contributions of each author**

Author 1 - Xiaofeng Ni.

Author 2 - Lingli Zhang.